Is the price fair?
What NEOG's price assumes
Neogen Corporation did not earn a profit over the last twelve months, so it has no trailing P/E and the price is read against sales instead: 2.81× revenue.
2.81
Price / sales · no P/E: the last twelve months did not end in a profit
- Free cash flow yield
- 0.30%
Free cash flow yield · Medical Devices median 4.0%
- Growth the price implies
- +45%
Growth the price implies · The price pays for +45% free cash flow growth a year for a decade; revenue has grown +6.5% a year over the last three.
- Price / book
- 1.16
Price / book · as of 2026-Q1
Details›
- Price / book2026-Q1
- 1.16
- EV / EBIToperating margin −73%: the multiple describes the denominator
- not meaningful
- EV / sales2026-Q1
- 3.54
- Free cash flow, trailing twelve months
- $6.0M
- Market capitalisation
- $2.03B
- 3-year revenue growth
- +6.5%
Multiples from SEC filings and end-of-day closes; implied growth from a reverse discounted cash flow. Group medians across the names Ryufin tracks.